Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-101 + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Oncotelic Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
**OT-101 + mFOLFIRINOX** is an investigational combination therapy comprising OT-101, an antisense oligonucleotide targeting transforming growth factor-beta 2 (TGF-β2), and mFOLFIRINOX, a modified chemotherapy regimen containing oxaliplatin, irinotecan, leucovorin (folinic acid), and fluorouracil (5-FU). OT-101 is designed to inhibit the immunosuppressive effects of TGF-β2 in the tumor microenvironment, potentially enhancing anti-tumor immune response and the efficacy of chemotherapy. mFOLFIRINOX is a dose-modified regimen used primarily as first-line therapy for advanced or metastatic pancreatic cancer and aims to balance effectiveness with reduced toxicity. The combination is currently under investigation as a first-line treatment for advanced, unresectable, or metastatic pancreatic cancer, with ongoing phase IIb/III clinical trials evaluating its safety and efficacy[1][3][5][7].
- Other names
- OT-101 plus mFOLFIRINOXOT101 plus mFOLFIRINOXOT 101 plus mFOLFIRINOXOT-101 and mFOLFIRINOXOT101 and mFOLFIRINOXOT 101 and mFOLFIRINOX
02
Targets
TS (Thymidylate synthase)MicrotubuleTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on OT-101 + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-101 + mFOLFIRINOX.